Rivaroxaban induced spontaneous hemoperitoneum around terminal ileum and cecum clinically mimicking acute appendicitis in a young patient: First case report

Ibrahim Halil Inanc 1 * , Saadet Kılıc 2, Murat Polat 3
More Detail
1 Department of Cardiology, Besni State Hospital, Adiyaman, Turkey
2 Department of General Surgery, Besni State Hospital, Adiyaman, Turkey
3 Department of Radiology, Faculty of Medicine, Adnan Menderes University, Aydın, Turkey
* Corresponding Author
J CLIN MED KAZ, Volume 2, Issue 56, pp. 50-52. https://doi.org/10.23950/1812-2892-JCMK-00756
OPEN ACCESS 1741 Views 1401 Downloads
Download Full Text (PDF)

ABSTRACT

Direct oral anticoagulants have become more popular in recent years and have largely replaced vitamin K antagonists in the treatment of certain conditions, such as stroke prevention in atrial fibrillation and venous thromboembolism. Rivaroxaban is one of the direct oral anticoagulants that inhibit factor Xa and a rare cause of peritoneal haemorrhage which is uncommon and life-threatening complication. In this report, we present a 29-year-old female patient using rivaroxaban due to deep vein thrombosis after pregnancy and developing intraperitoneal hemorrhage around terminal ileum and cecum clinically mimicking acute appendicitis.

CITATION

Inanc IH, Kılıc S, Polat M. Rivaroxaban induced spontaneous hemoperitoneum around terminal ileum and cecum clinically mimicking acute appendicitis in a young patient: First case report. Journal of Clinical Medicine of Kazakhstan. 2020;2(56):50-2. https://doi.org/10.23950/1812-2892-JCMK-00756

REFERENCES

  • Beyer-Westendorf J, Förster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, The Journal of the American Society of Hematology. 2014; 124(6):955-62. https://doi.org/10.1182/blood-2014-03-563577
  • Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Reviews. 2017; 31(4):193-203. https://doi.org/10.1016/j.blre.2017.02.001
  • Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clinical pharmacokinetics. 2014; 53(1):1-16. https://doi.org/10.1007/s40262-013-0100-7
  • Cheung K-S, Leung WK. Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management. World journal of gastroenterology. 2017; 23(11):1954. https://doi.org/10.3748/wjg.v23.i11.1954
  • Douxfils J, Ageno W, Samama CM, Lessire S, Ten Cate H, Verhamme P, et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. Journal of Thrombosis and Haemostasis. 2018; 16(2):209-19. https://doi.org/10.1111/jth.13912
  • Investigators E. Oral rivaroxaban for symptomatic venous thromboembolism. New England Journal of Medicine. 2010; 363(26):2499-510. https://doi.org/10.1056/NEJMoa1007903
  • Naseem Z, Mustaev M, Strekozov B. Spontaneous splenic rupture secondary to rivaroxaban: Rare but raising. IJSM. 2016; 2:134-6. https://doi.org/10.5455/ijsm.spleenrupture
  • Krause M, Henningsen A, Torge A, Juhl D, Junker R, Kenet G, et al. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism. Thrombosis research. 2016; 148:145-51. https://doi.org/10.1016/j.thromres.2016.09.007
  • Sherrod BA, Condie CK, Brock AA, Ledyard H, Menacho ST, Mazur MD. Emergent Reversal of Direct Oral Anticoagulants Permitting Neurosurgical Intervention for Nonhemorrhagic Pathology. World Neurosurgery. 2020; 135:38-41. https://doi.org/10.1016/j.wneu.2019.11.162